EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review

Shariq Ahmad Wani iD, Salma Qudrat iD, Hina Zubair, Zahra Iqbal, Babar Gulzar, Sundal Aziz, Arsalan Inayat, Danish Safi, Amir Kamran

Journal of Oncology Pharmacy Practice · 2025

DOI: 10.1177/10781552241275943 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Oncology Pharmacy Practice, 2025. Verfasst von Shariq Ahmad Wani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Government medical college, Srinagar, India. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bone Neoplasms, Osteoclasts, Bone Density Conservation Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To study the role of Osteoclast inhibitors in advanced prostate cancer metastasis treatment and their efficacy in reducing skeletal related events.

Methods

Data Source A comprehensive search was done using search terms as “osteoclast inhibitors” “Bisphosphonates” “Zoledronic acid” “ pamidronate” “ Alendronate” “Denosumab” “ Prostate cancer metastasis” in pubmed and Google scholar. Relevant articles were screened and collected . The collected articles were used to frame the review and data showing use of Osteoclast inhibitors In prostate cancer bone metastasis was collected. Data summary Prostate cancer metastasizes most commonly to the skeleton thus leading to significant morbidity ranging from pain, pathological fractures to spinal cord compression and are the primary cause of patient disability and reduced quality of life.Initially, radiation therapy and radiopharmaceuticals were the mainstay of treatment however the role of Bisphosphonates and denosumab has become an integral part of therapy to manage metastatic prostate cancer. These agents significantly decrease skeletal related events and enhance patients quality of life. Emerging therapies like Radium-223 have also shown promise in reducing skeletal related events and also improving survival rates in patients with bone metastasis. Other treatment options which are being used are systemic agents like Docetaxel, cabazitaxel, hormonal therapies like abiraterone and enzalutamide. Immunotherapy with sipuleucel-T has demonstrated a reduction in mortality among prostate cancer patients with metastasis, highlighting the need for further research in this area. Ongoing studies are investigating novel agents that target both tumor cells and the bone microenvironment.

Conclusion

Osteoclast inhibitors are effective in reducing skeletal related events in advanced bone metastasis and improve the quality of life of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBone NeoplasmsOsteoclastsBone Density Conservation AgentsHumansMaleQuality of LifeDenosumabDiphosphonates

Stichwörter der Autor:innen

Bonebisphosphonatesmetastasisosteoclast inhibitorsprostate cancer

Substanzen

Bone Density Conservation AgentsDenosumabDiphosphonates

Autor:innen und Institutionen

  • Department of Internal Medicine, Government medical college, Srinagar, India.
  • internal Medicine, Khyber teaching hospital, Peshawar, Pakistan.
  • Internal Medicine, Rawalpindi medical university, Rawalpindi, Pakistan.
  • Internal Medicine, Virginia commonwealth university, Richmond, USA.
  • Internal Medicine, Khyber medical university, Peshawar, Pakistan.
  • Internal Medicine, HSHS St Mary's Hospital, Decatur, Illinois, USA.

ORCID-Profile: Shariq Ahmad Wani, Salma Qudrat

Zitieren

APA

Wani, S. A., Qudrat, S., Zubair, H., Iqbal, Z., Gulzar, B., Aziz, S., Inayat, A., Safi, D., & Kamran, A. (2025). Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552241275943

Vancouver

Wani SA, Qudrat S, Zubair H, Iqbal Z, Gulzar B, Aziz S, et al. Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review. Journal of Oncology Pharmacy Practice. 2025. doi:10.1177/10781552241275943

BibTeX
@article{Wani2025,
  author = {Wani, Shariq Ahmad and Qudrat, Salma and Zubair, Hina and Iqbal, Zahra and Gulzar, Babar and Aziz, Sundal and Inayat, Arsalan and Safi, Danish and Kamran, Amir},
  title = {Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2025},
  doi = {10.1177/10781552241275943}
}
Kostenlos starten →